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Alzheimer’s disease (AD) is a progressive fatal neurodegenerative disorder and the most 
common type of dementia. It is manifested by a variety of neuropsychiatric symptoms such as 
memory loss, visuospatial deficits etc. Ethiology of the disease has a multifactorial character 
and is not well known. Among the major pathological features belong: presence of 
extracellular amyloid plaques, intracellular aggregates of hyperphosphorylated tau protein 
and neuronal loss, especially loss of cholinergic neurons. Also the oxidative stress of the 
neuronal cells contributes to the pathophysiology of the disease. As AD is influenced by 
multiple factors, the main strategy in treatment is hitting multiple targets in the brain as well. 
Such drugs are denoted as multi-target-directed ligands (MTDLs) and they affect different 
molecular abnormalities of AD. Within this work, we would like to bring out new 
tacrine - benzothiazole hybrids combining tacrine with the amino benzothiazole moiety. 
Linkers of different lenghts were used to connect these two scaffolds. Tacrine was the first 
drug approved for AD treatment by FDA. Its mechanism of action is based on inhibition 
of cholinesterases and thereby increasing the level of synaptic acetylcholine. On the other 
hand, benzothiazole, as a planar molecule, could prevent the protein-protein interactions and 
thus it could exhibit potential anti-amyloid effect. Moreover, benzothiazole moiety represents 
a core scaffold of inhibitors of amyloid-binding alcohol dehydrogenase (ABAD). ABAD is a 
mitochondrial enzyme that contributes to oxidative stress in AD progression. Therefore, its 
inhibition could avoid ROS production and act neuroprotectively. Based on the above-
mentioned facts, molecules bearing tacrine and benzothiazole skeleton could become 
promising drug candidates in AD therapy. Nevertheless, just in vitro and in vivo evaluation of 
biological activity will reveal their real value in the field of Alzheimer’s disease. This work 
includes synthesis of new compounds and their in vitro evaluation of acetylcholinesterase and 
butyrylcholinesterase inhibition. They exerted bio-activity in micromolar and nanomolar 
concentration. 
 
